Tirzepatide vs Semaglutide

Tirzepatide and semaglutide are the two most clinically powerful GLP-1 medications available in 2026. Both produce significant weight loss in adults with obesity, but they work through different mechanisms and have meaningfully different clinical profiles. This guide compares them across efficacy, mechanism, cost, side effects, cardiovascular evidence, and FDA-approved indications.

Mechanism: dual incretin vs single incretin

Tirzepatide is the first-in-class dual GIP and GLP-1 receptor agonist. By simultaneously activating two incretin pathways — glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) — it produces synergistic effects on insulin secretion, appetite suppression, gastric emptying, and central food-reward signaling.

Semaglutide activates only the GLP-1 receptor. The mechanism produces appetite suppression, slowed gastric emptying, and glucose-dependent insulin secretion — but without the additional GIP-mediated effects. The dual mechanism is the leading scientific hypothesis for why tirzepatide outperforms semaglutide in head-to-head trials.

Efficacy: weight loss magnitude in head-to-head data

For years, comparisons between tirzepatide and semaglutide relied on indirect cross-trial analysis. That changed with SURMOUNT-5, the first head-to-head obesity trial published in late 2024, which compared tirzepatide to semaglutide 2.4 mg (Wegovy) in adults with obesity. Tirzepatide produced substantially greater weight loss than semaglutide 2.4 mg over the study period.

For type 2 diabetes, the SURPASS-2 trial (NEJM 2021) directly compared tirzepatide to semaglutide 1 mg (the Ozempic dose at the time). All three tirzepatide doses (5, 10, 15 mg) produced greater A1C reductions and weight loss than semaglutide 1 mg.

Bottom line on efficacy: Tirzepatide produces greater absolute weight loss than semaglutide in both head-to-head and indirect comparisons. The magnitude difference is meaningful — typically 4–6 percentage points of additional weight loss at maximum doses.

Cardiovascular outcomes: semaglutide has the edge in 2026

This is the one major area where semaglutide currently leads tirzepatide.

• Semaglutide: The SELECT trial (NEJM 2023) demonstrated a 20% reduction in major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. This led to Wegovy's March 2024 FDA approval for cardiovascular risk reduction.
• Tirzepatide: The SURPASS-CVOT trial is ongoing as of 2026 and will provide tirzepatide's dedicated cardiovascular outcomes data. Until then, tirzepatide's cardiovascular labeling rests on the cardiovascular safety analysis from SURPASS-4.

FDA-approved indications

Tirzepatide (as Mounjaro and Zepbound)

• Type 2 diabetes (Mounjaro, May 2022)
• Chronic weight management (Zepbound, November 2023)
• Moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, December 2024 — first medication ever approved for this indication)

Semaglutide (as Ozempic, Wegovy, and Rybelsus)

• Type 2 diabetes (Ozempic, December 2017)
• Cardiovascular risk reduction in type 2 diabetes with established CVD (Ozempic, 2020)
• Chronic weight management in adults (Wegovy, June 2021)
• Chronic weight management in adolescents 12+ (Wegovy, December 2022)
• Cardiovascular risk reduction in adults with established CVD and overweight/obesity without diabetes (Wegovy, March 2024)
• Type 2 diabetes — oral formulation (Rybelsus, September 2019)

Cost in 2026

Self-pay prices from the manufacturers (the FDA-approved products):

• Zepbound (tirzepatide) through LillyDirect: $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5–15 mg when each refill is within 45 days; otherwise $499 at 7.5 mg and $699 at 10–15 mg (LillyDirect page archived September 30, 2026).
• Wegovy (semaglutide) pen through NovoCare: $349 a month at every dose, with $199 for the first two fills of 0.25 mg and 0.5 mg for new patients through December 31, 2026; Wegovy HD 7.2 mg is $399.
• Wegovy pill (oral semaglutide): $149 for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg (NovoCare).

Compounded versions are not FDA-approved and are not the same products. Telehealth prices for them are tracked in our October 2026 price index. NexLife, our #1 pick, charges $169 a month month-to-month or $139 a month on its 12-month plan for compounded tirzepatide, and $139 or $119 for compounded semaglutide, at the same price at every dose (nexlife.us, read October 15, 2026).

Side effects: comparable profiles

Both medications share the GLP-1 class side-effect profile. The most common are gastrointestinal — nausea, diarrhea, vomiting, constipation, decreased appetite — typically dose-dependent and concentrated during titration. Both carry an FDA boxed warning for thyroid C-cell tumor risk and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

Dosing and administration

• Tirzepatide: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly
• Semaglutide (Wegovy): 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly

Tirzepatide's terminal half-life is approximately 5 days; semaglutide's is approximately 7 days. Both support once-weekly dosing comfortably.

Which should you choose?

• Choose tirzepatide if maximizing weight loss is the primary goal, you don't have established cardiovascular disease driving the decision, and you're treated by a clinician comfortable managing the dose-response curve.
• Choose semaglutide (Wegovy) if you have established cardiovascular disease and want a medication with formally labeled cardiovascular risk reduction, or if you're at the highest end of GI side-effect sensitivity.
• Either is reasonable for most adults with obesity without established CVD; insurance coverage, cost, and provider preference often drive the final selection.

For tirzepatide specifically, see our telehealth program comparison, with NexLife as our #1 pick.

Frequently Asked Questions